Meta analysis:clinical effect of postoperative adjuvant chemotheropy in stageⅠnon-small cell lung ;cancer

Yuanyuan Chen,Bibo Wu,Bin Xiong
DOI: https://doi.org/10.3969/cma.j.issn.1674-0785.2014.08.022
2014-01-01
Abstract:Objective To assess clinical efficacy of postoperative adjuvant chemotheropy in the treatment of stageⅠnon-small cell lung cancer (NSCLC). Methods Several databases were searched, including the Pubmed, Embase, Cochrane Library, CNKI, VIP databases. Randomized controlled trials (RCT) were collected according to the inclusion criterias, the quality of included trials was evaluated and the data was extracted, then we used RevMan 5.0 software for meta analyses. Results Five RCTs involving 1839 patients with stage I NSCLC were included. All of them reported the random method, but with no detailed about the allocation concealment and whether the blind method was used. The results of meta analyses showed that five year overall survival in the adjuvant chemotheropy group was greater than the controll group(RR: 0.83, 95% CI: 0.70-0.98, P=0.03), the recurrence between the two groups was similar, the difference had no statistical significance (RR:0.65,95%CI:0.39-1.07,P=0.09). Also there was no diversity of the five year overall survival in stage IB between both groups (RR:0.90, 95%CI:0.74-1.08, P=0.26). Conclusions Postoperative adjuvant chemotheropy can improve the overall survival in stage I NSCLC, but the benefit of progress free survival and subgroups analysis is not clear. However, the existence of bias and unsufficient subgroup analysis would affect the demonstration level of the outcome, so more high-quality double-blind RCT are needed to offer more definitely evidence.
What problem does this paper attempt to address?